Clinical Study of Treatment for Vitiligo: Evaluating Efficacy and Safety of MK-6194

Terminated Phase 2 NCT06113328

Study Description

This clinical study aims to assess the effectiveness, safety, and tolerability of MK-6194 in treating non-segmental vitiligo. The study will focus on determining if MK-6194 is more effective than a placebo in improving the Facial Vitiligo Area Scoring Index (F-VASI) in participants. The study will last for 24 weeks, and its primary goal is to compare the percent change from baseline in F-VASI between MK-6194 and the placebo. Join this study to potentially discover a new treatment option for vitiligo.

Study Details

Registry ID:
NCT06113328
Conditions:
Non-segmental Vitiligo
Phase:
Phase 2
Target Enrollment:
169 participants
Start Date:
Age Range:
18–75 years
Healthy Volunteers:
No

Study Locations (94 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →